---
title: Our Pipeline of Innovative Therapeutic Products | Orchestra BioMed
---

[![Orchestra BioMed Logo](https://www.orchestrabiomed.com/hubfs/logo-light.png) ](https://www.orchestrabiomed.com/)

×

## Who we are

- [Our Approach](https://www.orchestrabiomed.com/our-approach)
- [Our People](https://www.orchestrabiomed.com/our-people)
- [Careers](https://www.orchestrabiomed.com/careers)

## Our Innovations

- [Pipeline](https://www.orchestrabiomed.com/pipeline)
- [Therapeutic Areas](https://www.orchestrabiomed.com/therapeutic-areas)
- [AVIM Therapy](https://www.orchestrabiomed.com/avim-therapy)
- [Virtue® SAB](https://www.orchestrabiomed.com/virtue-sab)

## Content Hub

## Investor Relations

- [Overview](https://investors.orchestrabiomed.com)
- [News & Events](https://investors.orchestrabiomed.com/news-and-events)
- [Stock Quote & Chart](https://investors.orchestrabiomed.com/stock-quote-and-chart)
- [Analyst Coverage](https://investors.orchestrabiomed.com/analyst-coverage)
- [Corporate Governance](https://investors.orchestrabiomed.com/corporate-governance)
- [Financial & Filings](https://investors.orchestrabiomed.com/financials-and-filings)
- [IR Resources](https://investors.orchestrabiomed.com/ir-contact)

[![Orchestra BioMed Logo](https://www.orchestrabiomed.com/hubfs/logo-light.png) ]({type=EXTERNAL,%20content_id=null,%20href=,%20href_with_scheme=})

☰

# Our Pipeline

##### Advancing a multi-asset pipeline of high-impact therapeutic solutions

 Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential  
 for value creation using our partnership-enabled business model

[![wait](https://www.orchestrabiomed.com/hubfs/Assets%202024/ORCHESTRA_PIPELINE_NEW_SECTION_2.jpg) ](https://www.orchestrabiomed.com/avim-therapy) [![wait](https://www.orchestrabiomed.com/hubfs/Assets%202024/ORCHESTRA_PIPELINE_NEW_SECTION_1.jpg) ](https://www.orchestrabiomed.com/virtue-sab)

#### Our flagship product candidates, AVIM Therapy and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:

![Icon](https://www.orchestrabiomed.com/hubfs/Assets%202024/Icon%20target.png)

Target mature therapeutic  
 device markets with significant  
 unmet needs.

![Icon](https://www.orchestrabiomed.com/hubfs/Assets%202024/Icon%20bulb.png)

Provide high-impact  
 procedure-based solutions  
 with rapid adoption potential.

![Icon](https://www.orchestrabiomed.com/hubfs/Assets%202024/Icon%20Growth.png)

Offer strategic and financial  
 benefits to a commercial  
 partner and Orchestra BioMed.

* Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for:

1. The balloon dilation of the stenotic portion (up to 26 mm in length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter.

2. The balloon dilation of the de novo stenotic portion (up to 28 mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter.

3. The balloon dilation of the stenotic portion (up to 18 mm in length) of an infrapopliteal artery (P-3 segment or distal, below the knee) with a reference vessel diameter (RVD) of 2.25 to 4.0 mm, for the purpose of improving lumen diameter.

Virtue® SAB is investigational and not commercially approved.

AVIM therapy is investigational and not commercially approved.